Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial

Autor: Bio Joo, Joong Bae Ahn, Sang Joon Shin, Myeong-Jin Kim, Mi-Suk Park, Yeo Eun Kim
Rok vydání: 2016
Předmět:
Adult
Male
Vascular Endothelial Growth Factor A
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
Colorectal cancer
Contrast Media
Kaplan-Meier Estimate
Disease-Free Survival
Colorectal neoplasms
Metastasis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
FOLFOX
Dynamic contrast enhanced-magnetic resonance imaging
Internal medicine
Biomarkers
Tumor
medicine
Humans
Aged
Placenta Growth Factor
medicine.diagnostic_test
business.industry
Interleukin-8
Liver Neoplasms
Hazard ratio
Magnetic resonance imaging
Middle Aged
medicine.disease
Magnetic Resonance Imaging
Vascular endothelial growth factor
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Original Article
business
medicine.drug
Zdroj: Cancer Research and Treatment : Official Journal of Korean Cancer Association
ISSN: 2005-9256
1598-2998
Popis: Purpose The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests. Results The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.
Databáze: OpenAIRE
Externí odkaz: